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A B S T R A C T
Purpose: We sought to investigate gender-related differences in clinical outcomes after peripheral vascular in-
terventions (PVIs) from retrograde access in patients with chronic total occlusions (CTOs) of the infrainguinal
arteries.
Patients and methods: A total of 939 consecutive patients undergoing PVI were enrolled in the study. Patients
with peripheral artery diseases (PAD) and CTOs were treated with PVI from retrograde access according to the
local protocol. The participants were divided according to gender. Retrograde access included distal puncturing
to reach the CTO. The mean follow-up lasted 1,144.9 ± 664.3 days. Baseline characteristics, procedural and
long-term outcomes were compared according to gender.
Results: Women represented 37.4% of the study population, and more frequently suffered from hypertension
(92% vs. 86%, p = 0.001) and diabetes (54% vs. 46%, p = 0.02). Males more often presented with chronic
obstructive pulmonary disease (14.8% vs. 6.8%, p = 0.0003), coronary artery disease (45.4% vs. 32.7%,
p = 0.0001), smoking (60.4% vs. 45%, p = 0.007) and prior PVI (25% vs. 17%, p = 0.005). The Kaplan-Meier
survival curves at 5 years did not reveal gender-related differences in mortality (p = 0.8), whereas men were at a
significantly higher risk of re-PVI during the follow-up period (p = 0.047). Male gender was an independent
predictor of re-PVI (Hazard ratio: 1.276; 95% confidence interval: 1.015–1.614, p = 0.03).
Conclusion: Males are at increased risk of re-PVI compared to females with PAD and CTOs of infrainguinal
arteries treated with PVI from retrograde access.
1. Introduction
Peripheral artery disease (PAD) is an age-related, increasing social,
economic and medical condition [1]. Although changing lifestyle plays
an important role in PAD treatment, advanced stages of the disease
often require peripheral vascular intervention (PVI). At many experi-
enced academic centers, interventional methods have become the first-
line of treatment allowing limb-salvage procedures in patients with an
operative risk that precludes open surgery. The retrograde approach is
used in selected cases when conventional endovascular techniques fail
in occlusion management. Retrograde access includes distal puncturing
to reach the obstruction, and depending on the location of the lesion,
covering various locations, this includes pedal access. Publications are
available regarding predictors of clinical outcomes in patients with PAD
treated with angioplasty [2,3]. Clinical evaluation was mainly based on
the frequency of amputations and revascularizations, which are re-
ferred to as major adverse lower-limb events (MALE), and mortality.
Among the confirmed predictors of amputations in patients with PAD
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treated with antegrade access, we may find, for example: ulcerations,
increased serum C-reactive protein level, diabetes mellitus or younger
age [2]. While the predictors of survival include body-mass index, non-
ambulatory status or lower left ventricle ejection fraction [2]. The re-
lationship between gender and clinical presentation, treatment and
outcomes in patients with PAD undergoing PVI, has been investigated
in several studies [4]. Varying incidences of PAD among men and
women depending on the age group have been reported [1]. Also,
differences in the results of PAD treatment between women and men
are seen in many factors, such as the prevalence of comorbidities (in-
cluding diabetes), the frequency of PAD diagnosis and endovascular
treatment, vascular diameter, the age at treatment or procedural factors
[1]. The published studies are not consistent in predicting outcomes
after endovascular treatment in patients with PAD, and some of them
revealed poorer outcomes in females [5,6], while the others showed no
gender-related differences [6]. The relationship between gender and
outcomes in patients with PAD and chronic total occlusions (CTOs),
treated with PVI from retrograde access, is less investigated. Due to
more advanced atherosclerosis, usually disseminated, multi-segmental,
and in many cases, presented as critical lower limb ischemia, the results
in this group of patients may differ significantly from those treated from
antegrade access. The features mentioned above, including CTO of the
infrainguinal arteries, different clinical image and other spectrums of
atherosclerosis risk factors, may have an impact on the clinical out-
comes and their relationship with gender. What is more, so far, they
have not been analyzed in such a large group of patients.
The aim of the current study was to assess the relationship between
gender and long-term clinical outcomes in patients with PAD and CTOs
treated with endovascular interventions and retrograde access.
2. Patients and methods
2.1. Study population
This research was planned as a prospective observational study of
consecutive patients who underwent retrograde recanalization of CTO
localized in the superficial femoral artery (SFA), popliteal artery (PA) or
below-the-knee arteries. At three experienced and collaborating cen-
ters, we enrolled all consecutive patients after at least one unsuccessful
antegrade recanalization of CTO, qualified for the retrograde approach.
The cohort of this study consisted of 939 consecutive patients, among
whom 588 were men (62.6%). Females were significantly older in
comparison to males (71 ± 10.8 years vs. 65.8 ± 10 years, p < 0.0001)
(Table 1).
Antegrade failure was defined as inability to wire the distal part of
the vessel after the occlusion via access site, located in the contralateral
artery or proximal to the CTO lesion. According to the local protocol,
patients were screened for concomitant diseases, risk factors and
medication prior to the procedure. In all patients before the procedure,
ankle-brachial index was examined and severity of PAD was assessed
according to the Rutherford and/or Fontaine scales.
2.2. Methods
The decision regarding retrograde recanalization and access site was
based on prior angiography. The procedure of retrograde recanalization
was performed under local anesthesia and required two access sites:
antegrade and retrograde. Both proximal and distal punctures were
performed under the guidance of vascular ultrasound and/or fluoro-
scopy. The selection of antegrade access site type was determined by
many factors, including anatomical conditioning, type of vascular le-
sions, technical possibilities, type of occlusion, its length and prob-
ability of blood flow restoration. For the proximal access site, the
contralateral femoral artery was usually used, and 6 French (Fr) vas-
cular sheaths were among the most popular. The distal access site was
usually chosen in the reconnection area of the artery (needle:
12–15 mm, 21G). In some cases, 4 Fr vascular sheaths were needed to
obtain support during the procedure. In a few cases, the distal access
site was also used for the revascularization of more peripheral parts of
the artery. A hydrophilic stiff, J-shaped 0.035’’ guidewire (Terumo
Corporation, Shibuya, Tokyo, Japan) was used for the antegrade access
site. Occlusions were crossed from the retrograde access site with a soft
V18 non-hydrophilic 0.018’’ guidewire (Boston Scientific,
Marlborough, Massachusetts, USA). After crossing the occlusion with a
wire via the retrograde approach, predilatation was performed using a
balloon catheter. Stent implantation was based on the decision of the
operator. After the procedure, the distal sheet was immediately re-
moved, and the proximal one was maintained up to 4 h when the fe-
moral artery was punctured, which was conditioned by unfractionated
heparin use. In periprocedural treatment, all patients received double
antiplatelet therapy: aspirin 75 mg – permanently, and clopidogrel
75 mg for 3 months, a high dose of statin and according to local pro-
tocol, low-molecular-weight heparin for 4 weeks. Additional treatment
was accordant with individual risk factors and comorbidities.
2.3. Follow-up
In the long term follow-up, which lasted 1,144.9 ± 664.3 days,
patients were evaluated for major adverse cardiac and cerebrovascular
events (MACCE) as well as MALE. Data were collected between 2006
and 2016. In this study, MACCE were predefined as death, stroke/
transient ischemic attack (TIA), myocardial infarction, percutaneous
coronary intervention (PCI) or coronary artery bypass grafting (CABG).
MALE was defined as amputation, target lesion re-intervention, target
vessel re-intervention and surgical treatment. Due to shortages in the
available database, the level of amputation was not highlighted in the
present study and alike high-, mid- and low-amputations, they were
included in the overall amputation rate. The protocol complied with the
Declaration of Helsinki, and all participants provided written informed
consent before enrollment.
Table 1
Baseline clinical characteristics.
Variables Female
N = 351
Male
N = 588
p
Age, years 71 ± 10.8 65.8 ± 10.6 <0.0001
BMI, kg/m2 26.8 ± 5 27.5 ± 5.4 0.33
Hypertension, % 91.4 86.4 0.02
Diabetes mellitus, % 54.1 46.3 0.02
Renal failure, % 16.2 15.6 0.81
Coronary artery disease, % 32.8 45.4 0.0001
Hyperlipidemia, % 77.8 87.8 0.15
Stroke/TIA, % 8.5 8.8 0.02
Smoking, % 45 60.4 0.008
COPD, % 6.8 14.8 0.0003
Prior PTA, % 17.1 25 0.005
Acute limb ischemia, % 6 4.4 0.28
Critical limb ischemia, % 61.5 53.1 0.01
Intermittent claudication, % 32.5 42.9 0.002
Fontaine scale, %
1 0.3 0 0.002
2A 4.8 5.4
2B 29.3 37.4
3 15.7 18.4
4 49.9 38.6
Rutherford scale, %
1 3.7 5.1 0.0002
2 12.2 19.7
3 16.2 17.3
4 17.1 18.9
5 17.1 13.3
6 33.6 25.7
Abbreviations: COPD - chronic obstructive pulmonary disease; BMI - body mass
index; PTA - percutaneous transluminal angioplasty; TIA - transient ischemic
attacks.
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2.4. Statistical analysis
Continuous variables are expressed as mean ± standard deviation
or median and interquartile range. Categorical variables are introduced
as numbers and percentages. Normality of distribution was assessed
with the Shapiro-Wilk test. The Mann Whitney U test was used for non-
normally distributed continuous variables. Survival analyses were
performed using the Kaplan-Meier method while univariate and mul-
tivariate Cox regression analyses were used to find significant pre-
dictors of re-PVI during the follow-up. All baseline characteristics and
procedural data were tested as possible co-variates. Results are pre-
sented as hazard ratios (HR) with 95% confidence intervals (CI). All
tests were two-tailed and the p-value < 0.05 was considered statisti-
cally significant. All analyses were performed with JMP®, Version
13.1.0 (SAS Institute INC., Cary, NC, USA). The sample size was not
counted because the present study was based on the database registry,
the original purpose of which was not to assess the impact of gender on
clinical outcomes. All calculated analyzes were lesion-based. In the case
of bilateral involvement, one limb was included in the analysis and this
was recognized as one PVI, which in some cases, could be multi-seg-
mental. The treated lesion concerned the limb which was clinically
more affected by ischemia.
2.5. Ethical issues
The study protocol complied with the 1964 Declaration of Helsinki
with its later amendments, and all participants provided informed
written consent before enrollment. The protocol of the current study
has not been approved by local bioethics committee, due to its retro-
spective nature, and no consent is required for such type of a study.
3. Results
3.1. Clinical features
In general, there were significant differences between genders when
considering concomitant diseases. Men more frequently presented with
coronary artery disease (45.4% vs. 32.7%, p = 0.0001), chronic ob-
structive pulmonary disease (COPD; 14.8% vs. 6.8%, p = 0.0003) and
were more often smokers (60.4% vs. 45%, p = 0.007), while women
more often suffered from hypertension (91.4% vs. 86.4%, p = 0.001)
and diabetes (54.1% vs. 46.3%, p = 0.02). The baseline characteristics
of the population are shown in Table 1.
3.2. Procedural indices and biochemical parameters
Hemoglobin and creatinine concentrations in the serum were sta-
tistically significantly lower in females compared to males (p = 0.0048
and p = 0.0005, respectively). There were no statistically significant
differences between genders in procedure and fluoroscopy time, con-
trast volume or time from procedure to discharge, whereas the overall
hospitalization time was statistically significantly longer in females
(p = 0.0094). Females were qualified for the procedure with more
advanced and disseminated atherosclerotic lesions according to the
Trans-Atlantic Inter-Society Consensus (TASC) II classification. The
procedural success rate attained 88.8% and there were no statistically
significant differences between both groups. Women suffered from in-
traprocedural complications more often (7.93% vs. 5.40%,
p = 0.0094), including residual dissection (5.79% vs. 2.58%,
p = 0.02). This is presented in Table 2.
3.3. Clinical outcomes
There were no statistically significant differences between males
and females in the frequency of particular study endpoints which in-
cluded: strokes/TIA (p = 0.5), myocardial infarctions (p = 0.7),
amputations (p = 0.07), deaths (p = 0.68), lower limb bypasses
(p = 0.74) and percutaneous thrombectomies or thromboendarter-
ectomies (p = 0.15). Also, the mean time to the first adverse event did
not differ statistically significantly between males and females during
the follow-up period for these particular study endpoints (Table 3). Men
were at a higher risk of re-PVI at the 60-month follow-up (41.2% vs.
35.8%; p = 0.047). Re-PVI free survival probability for men and
women is shown in Fig. 1. The male gender was found in univariate and
multivariate Cox regression analysis to be an independent predictor of
re-PVI (HR: 1.276; 95% CI: 1.015–1.614, p = 0.03). Univariate and
multivariate Cox regression analyses confirmed that alongside gender,
chronic occlusion of superficial femoral artery (HR: 1.71; 95% CI:
1.11–2.68, p = 0.013) and procedural failure (HR: 2.15; 95% CI:
1.06–3.96, p = 0.03) were also statistically significant predictors of re-
PVI. After adjustment to male gender, re-PVI was statistically sig-
nificantly associated with diabetes (HR:1.19; 95% CI 0.95–1.48,
p = 0.03), COPD (HR: 0.75; 95% CI: 0.51–1.07, p = 0.03), prior PVI
(HR: 1.34; 95% CI: 1.04–1.71, p = 0.008) and age (HR: 0.99; 95% CI:
0.98–1.001, p = 0.02).
Table 2
Biochemical, procedural and atherosclerotic lesion characteristics.
Variables Female
N = 351
Male
N = 588
p
Hemoglobin, g/dL 12.9 ± 1.3 13.9 ± 1.7 0.005
Platelet count, *1000/μL 228.9 ± 59.2 209.3 ± 64.2 0.07
Creatinine, μmol/L 75.9 ± 23.8 91 ± 26.5 0.0005
eGFR mL/min/1.73 m2 54.3 ± 12 57.5 ± 9.2 0.044
Procedure time, sec 2737.2 ± 1834.4 2768.2 ± 2039.4 0.6
Fluoroscopy time, sec 812.1 ± 584.1 832.9 ± 759.5 0.4
Contrast volume, mL 112.9 ± 69.7 126.1 ± 92.7 0.26
Intraprocedural
complications, %
7.9 3.8 0.009
Time from PTA to discharge,
days
3.5 ± 1.9 3.1 ± 2.3 0.53
Hospitalization time, days 5.7 ± 4.9 5.2 ± 5.2 0.009
TASC II classification, %
A 14.6 21.6 0.003
B 17.7 21.6
C 15.7 14.6
D 52 42.2
Abbreviations: GFR - glomerular filtration rate; PTA - percutaneous translum-
inal angioplasty; TASC - Trans-Atlantic Inter-Society Consensus.
Table 3
Clinical outcomes.
Variables Female
N = 351
Male
N = 588
P
Re-PTA, % 30.86 36.93 0.059
Time to re-PTA, days 354.66 ± 456.6 331.33 ± 479.1 0.12
Stroke/TIA, % 3.14 2.44 0.52
Time to stroke/TIA, days 277.82 ± 359.9 70.3.86 ± 882.5 0.11
Myocardial infarction (MI), % 3.72 3.31 0.73
Time to MI, days 838.92 ± 640.6 773.11 ± 589.4 0.76
Death, % 14 13.07 0.68
Time to death, days 574.4 ± 657.8 616.68 ± 584.3 0.51
Amputation, % 19.94 15.26 0.07
Time to amputation, days 127.79 ± 193.4 184.53 ± 439.4 0.46
Lower extremity bypass (LEB),
%
5.43 4.92 0.74
Time to LEB 231.88 ± 298.1 254.71 ± 299.78 0.9
PTE/TEA, % 0.32 1.43 0.15
Time to PTE/TEA, days 6 ± 0 76 ± 77.3 0.27
Abbreviations: PTA - percutaneous transluminal angioplasty; PTE - percuta-
neous thrombectomy; TEA - thromboendarterectomy; TIA - transient ischemic
attacks.
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4. Discussion
The main finding of the present study is that in the group of patients
with PAD and CTOs treated with PVI from retrograde access, males
were at a higher risk of re-PVI during the long-term follow-up period.
According to the available database, there could be at least a few ex-
planations for this observation. In our study, females represented 37.4%
of the cohort, which remains in line with data presented in studies re-
lated to PAD treatment and is sanctioned by many factors [1]. Among
them, we include age, poorer diagnosis of PAD in females, different
symptoms which are related to a different spectrum of concomitant
diseases such as diabetes and diabetic neuropathy [1]. Another issue is
that the incidence of PAD rapidly increases during the climacteric
period and after the fifth decade - it is at least equally frequent in both
genders [7]. The disparity between epidemiological data and re-
presentation of the trial cohort may be rooted in sociological issues. The
fact of the aging population as a progressive phenomenon is undeniable
and its structure demonstrates the subpopulation of women as a ma-
jority [8]. In older age, it is common to confuse symptoms of PAD with
osteoarthritis or osteoporosis. Females more often present asympto-
matic PAD [9]. It has been suggested that women are less likely to be
hospitalized or to undergo invasive procedures, and when they do, they
are older and afflicted with a more advanced disease, which is con-
cordant with the results of our study [10,11]. This explains why females
undergo PVI at an older age and at more advanced stages of the disease.
As confirmation, we may underline the fact that Rutherford’s category
III and IV occurred significantly more often in the female population
than in males. Also, according to the TASC II classification, more ad-
vanced atherosclerosis was found in females. This is a consequence of
differences in symptoms between genders. It can also be concluded that
the consequence of this is greater difficulty with crossing the CTO in
females, due to the fact that the atherosclerotic lesions are more ad-
vanced and occur at older age. Undoubtedly, it resulted in a greater
number of peri-procedural complications. This, however, was not re-
flected in the frequency of retrograde access procedures among gen-
ders. Despite the factors mentioned above, the frequency of re-PVI was
higher among men. Therefore, it can be suspected that there were other
factors outweighing and determining the greater re-PVI rate in men.
Both, diabetes and younger age, were confirmed as predictors of ne-
gative events in the group of patients with PAD undergoing PVI
[12,13]. A similar relationship was demonstrated for TASC lesions and
lower body-mass index, which is described as the obesity paradox [2,4].
It seems that factors such as coronary artery disease, younger age,
smoking, COPD and hyperlipidemia prevail over the location of
changes, clinical advancement or the presence of diabetes and have
determined the higher frequency of re-PVI in the follow-up period in
men. The other probable factors behind the lower re-PVI prevalence
during follow-up among women are their compliance with post-treat-
ment recommendations. More careful drug use and compliance with
lifestyle modification recommendations, related to smoking, physical
activity and diet, may be of crucial importance here. There are many
studies assessing the need for reinterventions after PVI, but the pre-
sented results are often discrepant. Davies et al. [14] reported a higher
frequency of repeated reinterventions in women. Similarly, DeRubertis
et al. [6] noted an association between female gender and a higher
incidence of reintervention. In a study investigating 3,338 patients
undergoing peripheral vascular interventions, Ferranti et al. [10] found
no significant differences between genders in terms of re-PVI. Analogic
data related to a retrograde technique are scarce and do not include
gender-related differences [15,16]. In the current study, male gender
was linked to more frequent incidences of reintervention in comparison
to women. It is an interesting finding regarding more advanced diseases
in females, which remains in line with reports stating that women,
despite more severe PAD, are less likely to undergo invasive procedures
than men [1]. The presented results are burdened with a certain
probability of bias and require further research among larger and more
diverse populations.
Female gender has been recognized as a risk factor for periproce-
dural complications. There are many studies documenting wound issues
after peripheral artery bypass surgery [17,18]. Development of PVI
improved rates of procedural intricacies in both women and men and
diminished the gap between these groups [19]. The results of our study
remain in line with the findings in previously published papers
[5,6,10]. In the present study, women had significantly higher in-
cidences of intraprocedural complications and minor vascular compli-
cations compared to men. Based on the clinical data of the study in
question, especially the age and stage of PAD, one may note that the
greater number of peri-operative complications is associated with
atherosclerotic lesions more challenging for the operator. This re-
lationship seems to be crucial regarding the difference in the frequency
of complications between women and men.
4.1. Limitations of the study
Several limitations could be attributed to the current study. One of
them is the sample size which may bring some bias to the present study.
Another potential factor is different completion time and shorter
duration in selected patients during the follow-up period. Additional
important limitation is the small number of procedural operators. There
was also a significant possibility that more ill patients had out-of-hos-
pital events and did not make it to follow-up.
5. Conclusions
Male gender was identified as an independent predictor of re-PVI in
the group of patients with PAD and CTOs treated with percutaneous
angioplasty from retrograde access. Chronic occlusion in the superficial
femoral artery and procedural failure were associated with re-PVI in
women. Further studies are needed to investigate gender disparities in
outcomes after retrograde access procedures.
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